




Instance: composition-en-f38fd388d9d557d533fdef41848d682d
InstanceOf: CompositionUvEpi
Title: "Composition for nustendi Package Leaflet"
Description:  "Composition for nustendi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf38fd388d9d557d533fdef41848d682d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nustendi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Nustendi is and what it is used for </li>
<li>What you need to know before you take Nustendi </li>
<li>How to take Nustendi </li>
<li>Possible side effects </li>
<li>How to store Nustendi </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nustendi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nustendi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nustendi is and how it works </p>
<p>Nustendi is a medicine that lowers levels of  bad  cholesterol (also called  LDL-cholesterol ), a type 
of fat, in the blood. </p>
<p>Nustendi contains two active substances, which reduce your cholesterol in two ways: 
* bempedoic acid decreases the production of cholesterol in the liver and increases the removal of 
LDL-cholesterol from the blood; 
* ezetimibe works in your bowel by reducing the amount of cholesterol absorbed from food. </p>
<p>What Nustendi is used for </p>
<p>Nustendi is given to adults with primary hypercholesterolaemia or mixed dyslipidaemia, which are 
conditions that cause a high cholesterol level in the blood. It is given in addition to a cholesterol-
lowering diet. </p>
<p>Nustendi is given: 
* if you have been using a statin (such as simvastatin, a commonly used medicine that treats high 
cholesterol) together with ezetimibe and this does not lower your LDL-cholesterol sufficiently; 
* if you have been using ezetimibe and this does not lower your LDL-cholesterol sufficiently; 
* to replace bempedoic acid and ezetimibe if you have been using these medicines as separate 
tablets. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nustendi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nustendi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Nustendi: </p>
<ul>
<li>if you are allergic to bempedoic acid, ezetimibe or any of the other ingredients of this medicine 
(listed in section 6); </li>
<li>if you are pregnant; </li>
<li>if you are breast-feeding; </li>
<li>if you take more than 40 mg of simvastatin daily (another medicine used to lower cholesterol); </li>
<li>with a statin if you currently have liver problems. </li>
<li>Nustendi contains ezetimibe. When Nustendi is given together with a statin, you should also 
read the information relating to ezetimibe in the Package leaflet of that specific statin. </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor or pharmacist before taking Nustendi: 
* if you ever had gout; 
* if you have severe kidney problems; 
* if you have moderate or severe liver problems. Nustendi is not recommended in this case. </p>
<p>Your doctor should do a blood test before you start taking Nustendi with a statin. This is to check how 
well your liver is working. </p>
<p>Children and adolescents </p>
<p>Do not give Nustendi to children and adolescents under 18 years of age. The use of Nustendi has not 
been studied in this age group. </p>
<p>Other medicines and Nustendi </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. In particular, tell your doctor if you are taking medicine(s) with any of the following active 
substances: 
* atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin (used to lower 
cholesterol and known as statins). 
The risk of muscle disease may increase when taking both a statin and Nustendi. Tell your 
doctor immediately about any unexplained muscle pain, tenderness or weakness. 
* bosentan (used to manage a condition called pulmonary artery hypertension). 
* fimasartan (used to treat high blood pressure and heart failure). 
* asunaprevir, glecaprevir, grazoprevir, voxilaprevir (used to treat hepatitis C). 
* fenofibrate (also used to lower cholesterol). 
No information is available on the effects of using Nustendi with cholesterol-lowering 
medicines called fibrates. 
* ciclosporin (often used in organ transplant patients). 
* colestyramine (also used to lower cholesterol), because it affects the way ezetimibe works. 
* medicines to prevent blood clots, such as warfarin as well as acenocoumarol, fluindione, and 
phenprocoumon. </p>
<p>Pregnancy and breast-feeding </p>
<p>Do not take this medicine if you are pregnant, trying to get pregnant, or think you may be pregnant, as 
there is a possibility that it could harm an unborn baby. If you get pregnant while taking this medicine, 
call your doctor immediately and stop taking Nustendi. </p>
<ul>
<li>Pregnancy 
Before starting treatment, you should confirm you are not pregnant and are using effective 
contraception, as advised by your doctor. If you use contraceptive pills and suffer from an 
episode of diarrhoea or vomiting that lasts more than 2 days, you must use an alternative method 
of contraception (e.g. condoms, diaphragm) for 7 days following resolution of symptoms. </li>
</ul>
<p>If, after you have started treatment with Nustendi, you decide that you would like to become 
pregnant, tell your doctor, as your treatment will need to be changed. </p>
<ul>
<li>Breast-feeding 
Do not take Nustendi if you are breast-feeding because it is not known if Nustendi passes into 
milk. </li>
</ul>
<p>Driving and using machines </p>
<p>Nustendi has minor influence on the ability to drive and use machines. </p>
<p>However, some people may get dizzy after taking Nustendi. Avoid driving or using machines if you 
think your ability to react is reduced. </p>
<p>Nustendi contains lactose and sodium </p>
<p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nustendi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nustendi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is one tablet once daily. </p>
<p>If you are taking colestyramine, take Nustendi either at least 2 hours before or at least 4 hours after 
taking colestyramine. </p>
<p>Swallow the tablet whole with food or between meals. </p>
<p>If you take more Nustendi than you should </p>
<p>Contact your doctor or pharmacist immediately. </p>
<p>If you forget to take Nustendi </p>
<p>If you notice that you forgot: 
* a dose late in a day, take the missed dose and take the next dose at your regular time the next 
day. 
* the previous day s dose, take your tablet at the regular time and do not make up for the forgotten 
dose. 
If you stop taking Nustendi </p>
<p>Do not stop taking Nustendi without your doctor s permission as your cholesterol may rise again. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Contact your doctor immediately if you have any of the following serious side effects (frequencies 
are unknown): 
* muscle pain or weakness 
* yellowish skin and eyes, abdominal pain, dark urine, swollen ankles, decreased appetite, and 
feeling tired that could be signs of liver problems 
* allergic reactions including rash and hives; raised red rash, sometimes with target-shaped lesions 
(erythema multiforme) 
* gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, 
vomiting), inflammation of the pancreas often with severe abdominal pain 
* reduction in blood platelets, which may cause bruising/bleeding (thrombocytopenia) </p>
<p>Other side effects can occur with the following frequencies: </p>
<p>Common (may affect up to 1 in 10 people) 
* lower number of red blood cells (anaemia) 
* decreased haemoglobin (a protein in red blood cells that carries oxygen) 
* increased levels of uric acid in blood, gout 
* decreased appetite 
* dizziness, headache 
* high blood pressure 
* cough 
* constipation, diarrhoea, abdominal pain 
* nausea 
* dry mouth 
* abdominal bloating and gas, inflammation of the stomach lining (gastritis) 
* blood test results indicating liver abnormalities 
* muscle spasm, muscle pain, pain in shoulders, legs or arms, back pain, blood test showing raised 
creatine kinase (a laboratory test of muscle damage), muscle weakness, joint pain (arthralgia) 
* raised creatinine and blood urea nitrogen (laboratory tests of kidney function) 
* unusual tiredness or weakness </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* hot flush 
* pain in the upper part of stomach, heartburn, indigestion 
* itching 
* swelling of the legs or hands 
* neck pain, chest pain, pain 
* decreased glomerular filtration rate (a measure of how well your kidneys are working) </p>
<p>Not known (frequency cannot be estimated from available data) 
* tingling sensation 
* depression 
* shortness of breath 
Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nustendi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nustendi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The 
expiry date refers to the last day of the month. </p>
<p>This medicine does not require any special temperature storage conditions. Store in the original 
package in order to protect from moisture. </p>
<p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Nustendi contains </p>
<ul>
<li>The active substances are bempedoic acid and ezetimibe. Each film-coated tablet contains 
180 mg of bempedoic acid and 10 mg of ezetimibe. </li>
<li>
<p>The other ingredients are:</p>
</li>
<li>
<p>lactose monohydrate (see end of section 2 under  Nustendi contains lactose and sodium ) </p>
</li>
<li>microcrystalline cellulose (E460) </li>
<li>sodium starch glycolate (Type A grade) (see end of section 2 under  Nustendi contains 
lactose and sodium ) </li>
<li>hydroxypropyl cellulose (E463) </li>
<li>magnesium stearate (E470b) </li>
<li>silica, colloidal anhydrous (E551) </li>
<li>sodium laurilsulfate (E487) (see end of section 2 under  Nustendi contains lactose and 
sodium ) </li>
<li>povidone (K30) (E1201) </li>
<li>partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171), 
Indigo Carmine Aluminium Lake (E132), glycerol monocaprylocaprate, Brilliant Blue FCF 
Aluminium Lake (E133) </li>
</ul>
<p>What Nustendi looks like and contents of the pack </p>
<p>Film-coated tablets are blue, oval, debossed with  818  on one side and  ESP  on the other side. 
Tablet dimensions: 15 mm   7 mm   5 mm. </p>
<p>Nustendi is supplied in plastic/aluminium blisters in cartons of 10, 14, 28, 30, 84, 90, 98 or 100 film-
coated tablets or unit dose blisters in cartons of 10 x 1, 50 x 1, or 100 x 1 film-coated tablets. </p>
<p>Not all pack sizes may be marketed in your country. 
Marketing Authorisation Holder </p>
<p>Daiichi Sankyo Europe GmbH 
Zielstattstrasse 81379 Munich 
Germany </p>
<p>Manufacturer </p>
<p>Daiichi Sankyo Europe GmbH 
Luitpoldstrasse 1 
85276 Pfaffenhofen 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Daiichi Sankyo Belgium N.V.-S.A 
T l/Tel: +32-(0) 2 227 18 Lietuva 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 </p>
<p>Daiichi Sankyo Europe GmbH 
 .: +49-(0) 89 7808 0 
Luxembourg/Luxemburg 
Daiichi Sankyo Belgium N.V.-S.A 
T l/Tel: +32-(0) 2 227 18  esk  republika 
Zentiva, k.s. 
Tel: +420 267 241 Magyarorsz g 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
Danmark 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 
Malta 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Deutschland 
Daiichi Sankyo Deutschland GmbH 
Tel: +49-(0) 89 7808 0 
Nederland 
Daiichi Sankyo Nederland B.V. 
Tel: +31-(0) 20 4 07 20 Eesti 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Norge 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 </p>
<p>Daiichi Sankyo Europe GmbH 
 : +49-(0) 89 7808 0 
 sterreich 
Daiichi Sankyo Austria GmbH 
Tel: +43 (0) 1 485 86 42 0 
Espa a 
Daiichi Sankyo Espa a, S.A. 
Tel: +34 91 539 99 Polska 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
France 
Daiichi Sankyo France S.A.S. 
T l: +33 (0) 1 55 62 14 Portugal 
Daiichi Sankyo Portugal, Unip. LDA 
Tel: +351 21 4232Hrvatska 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Rom nia 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Ireland 
Daiichi Sankyo Ireland Ltd 
Tel: +353-(0) 1 489 3Slovenija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
 sland 
Daiichi Sankyo Europe GmbH 
S mi: +49-(0) 89 7808 0 
Slovensk  republika 
Zentiva, a.s. 
Tel: +421 2 3918 3Italia 
Daiichi Sankyo Italia S.p.A. 
Tel: +39-06 85 2Suomi/Finland 
Daiichi Sankyo Europe GmbH 
Puh/Tel: +49-(0) 89 7808 0 </p>
<p>Daiichi Sankyo Europe GmbH 
 : +49-(0) 89 7808 0 
Sverige 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Latvija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
United Kingdom (Northern Ireland) 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 </p>
<p>This leaflet was last revised in {month YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-f38fd388d9d557d533fdef41848d682d
InstanceOf: CompositionUvEpi
Title: "Composition for nustendi Package Leaflet"
Description:  "Composition for nustendi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf38fd388d9d557d533fdef41848d682d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nustendi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Nustendi </li>
<li>Sådan skal du tage Nustendi </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nustendi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nustendi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Nustendi, og hvordan virker det? </p>
<p>Nustendi er et lægemiddel, der sænker niveauet af det såkaldt "dårlige" kolesterol (LDL-kolesterol), 
der er en type fedt i blodet. </p>
<p>Nustendi indeholder to aktive stoffer, der reducerer kolesterolet på to måder: </p>
<ul>
<li>
<p>Bempedoinsyre sænker produktionen af kolesterol i leveren og øger fjernelsen af LDL-
kolesterol fra blodet. </p>
</li>
<li>
<p>Ezetimib virker i tarmen ved at reducere den mængde kolesterol, der optages fra maden. </p>
</li>
</ul>
<p>Hvad anvendes Nustendi til? </p>
<p>Nustendi gives til voksne med primær hyperkolesterolæmi eller blandet dyslipidæmi, som er 
sygdomme, der forårsager et højt kolesterolniveau i blodet. Nustendi gives i tillæg til 
kolesterolsænkende diæt. </p>
<p>Nustendi gives: </p>
<ul>
<li>
<p>hvis du har brugt et statin (f.eks. simvastatin, et almindeligt anvendt lægemiddel til behandling 
af forhøjet kolesterol) sammen med ezetimib, uden at det har sænket dit LDL-kolesterol 
tilstrækkeligt </p>
</li>
<li>
<p>hvis du har brugt ezetimib, uden at det har sænket dit LDL-kolesterol tilstrækkeligt </p>
</li>
<li>
<p>i stedet for bempedoinsyre og ezetimib, hvis du har taget disse lægemidler som separate 
tabletter. </p>
</li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nustendi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nustendi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Nustendi: </p>
<ul>
<li>
<p>hvis du er allergisk over for bempedoinsyre, ezetimib eller et af de øvrige indholdsstoffer i 
Nustendi (angivet i punkt 6) </p>
</li>
<li>
<p>hvis du er gravid </p>
</li>
<li>
<p>hvis du ammer </p>
</li>
<li>
<p>hvis du tager over 40 mg simvastatin dagligt (et andet kolesterolsænkende lægemiddel) </p>
</li>
<li>
<p>sammen med et statin, hvis du aktuelt har leverproblemer </p>
</li>
<li>
<p>Nustendi indeholder ezetimib. Hvis Nustendi gives sammen med et statin, bør du også læse de 
oplysninger om ezetimib, der står i indlægssedlen for det pågældende statin. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Nustendi: </p>
<ul>
<li>
<p>hvis du tidligere har haft urinsyregigt </p>
</li>
<li>
<p>hvis du har alvorlige nyreproblemer </p>
</li>
<li>
<p>hvis du har moderate eller alvorlige leverproblemer. Nustendi anbefales ikke i disse tilfælde. </p>
</li>
</ul>
<p>Lægen bør tage en blodprøve, før du begynder at tage Nustendi sammen med et statin, for at se, hvor 
godt din lever fungerer. </p>
<p>Børn og unge </p>
<p>Nustendi må ikke gives til børn og unge under 18 år. Anvendelse af Nustendi er ikke undersøgt hos 
denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Nustendi </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. Fortæl det især til lægen, hvis du tager 
lægemidler, der indeholder nogen af følgende aktive stoffer: </p>
<ul>
<li>
<p>atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin eller simvastatin (såkaldte 
statiner, der sænker kolesterolniveauet). 
Risikoen for muskelsygdom kan øges ved samtidig anvendelse af et statin og Nustendi. Sig det 
til lægen med det samme, hvis du oplever uventet smerte, ømhed eller svaghed i musklerne </p>
</li>
<li>
<p>bosentan (til behandling af forhøjet blodtryk i lungearterierne) </p>
</li>
<li>
<p>fimasartan (til behandling af forhøjet blodtryk og hjertesvigt) </p>
</li>
<li>
<p>asunaprevir, glecaprevir, grazoprevir eller voxilaprevir (til behandling af hepatitis C) </p>
</li>
<li>
<p>fenofibrat (sænker også kolesterolniveauet). 
Der foreligger ingen oplysninger om effekten af samtidig anvendelse af Nustendi og fibrater 
(kolesterolsænkende midler) </p>
</li>
<li>
<p>ciclosporin (anvendes ofte hos organtransplanterede patienter) </p>
</li>
<li>
<p>colestyramin (sænker også kolesterolniveauet), da det påvirker ezetimibs virkemåde </p>
</li>
<li>
<p>lægemidler til forebyggelse af blodpropper, f.eks. warfarin, acenocoumarol, fluindion og 
phenprocoumon. </p>
</li>
</ul>
<p>Graviditet og amning </p>
<p>Du må ikke tage dette lægemiddel, hvis du er gravid, har mistanke om, at du er gravid, eller 
planlægger at blive gravid, da det muligvis kan være skadeligt for det ufødte barn. Hvis du bliver 
gravid, mens du tager dette lægemiddel, skal du straks kontakte lægen og holde op med at tage 
Nustendi. </p>
<ul>
<li>Graviditet 
Inden du påbegynder behandling, skal du bekræfte, at du ikke er gravid, og at du bruger sikker 
prævention som anvist af lægen. Hvis du bruger p-piller og oplever diarré eller opkastning, der 
varer mere end 2 dage, skal du bruge en anden præventionsmetode (f.eks. kondom eller pessar) i 
7 dage, efter at symptomerne har fortaget sig. </li>
</ul>
<p>Hvis du efter at være startet på Nustendi beslutter, at du ønsker at blive gravid, skal du sige det 
til lægen, da din behandling så skal ændres. </p>
<ul>
<li>Amning 
Du må ikke tage Nustendi, hvis du ammer, da det der ukendt, om Nustendi udskilles i 
modermælk. </li>
</ul>
<p>Trafik- og arbejdssikkerhed </p>
<p>Nustendi påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner. </p>
<p>Nogle kan imidlertid opleve svimmelhed, når de tager Nustendi. Undlad at føre motorkøretøj eller 
betjene maskiner, hvis du vurderer, at din reaktionsevne er nedsat. </p>
<p>Nustendi indeholder lactose og natrium </p>
<p>Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerartergal. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nustendi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nustendi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er én tablet én gang dagligt. </p>
<p>Hvis du tager colestyramin, skal du enten tage Nustendi mindst 2 timer inden eller mindst 4 timer 
efter, at du har taget colestyramin. </p>
<p>Tabletten skal synkes hel og kan tages med eller uden mad. </p>
<p>Hvis du har taget for meget Nustendi </p>
<p>Kontakt lægen eller apotekspersonalet med det samme. </p>
<p>Hvis du har glemt at tage Nustendi </p>
<p>Hvis du opdager, at du har glemt: </p>
<ul>
<li>
<p>at tage din dosis sent på dagen, skal du tage den glemte dosis og tage den næste dosis på det 
sædvanlige tidspunkt næste dag. </p>
</li>
<li>
<p>at tage din dosis dagen før, skal du tage din nye tablet på det sædvanlige tidspunkt; du må ikke 
tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Hvis du holder op med at tage Nustendi </p>
<p>Du må ikke holde op med at tage Nustendi uden lægens godkendelse, da dit kolesterol kan stige igen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Kontakt lægen med det samme, hvis du oplever en eller flere af følgende alvorlige bivirkninger 
(hyppighed ikke kendt): </p>
<ul>
<li>
<p>muskelsmerter eller muskelsvaghed </p>
</li>
<li>
<p>gulfarvning af hud og øjne, mavesmerter, mørk urin, hævede ankler, nedsat appetit og træthed 
(kan være tegn på leverproblemer) </p>
</li>
<li>
<p>allergiske reaktioner, herunder udslæt og nældefeber, hævet rødt udslæt, indimellem med 
skydeskiveformede læsioner (erythema multiforme) </p>
</li>
<li>
<p>galdesten eller galdeblærebetændelse (som kan give mavesmerter, kvalme og opkastning), 
betændelse i bugspytkirtlen (giver ofte kraftige mavesmerter) </p>
</li>
<li>
<p>nedsat antal blodplader (trombocytopeni - kan give blå mærker/blødning) </p>
</li>
</ul>
<p>Andre bivirkninger kan optræde med følgende hyppigheder: </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) </p>
<ul>
<li>
<p>nedsat antal røde blodlegemer (anæmi) </p>
</li>
<li>
<p>nedsat hæmoglobin (et protein i de røde blodlegemer, der transporterer ilt) </p>
</li>
<li>
<p>øget urinsyre i blodet, urinsyregigt </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>svimmelhed, hovedpine </p>
</li>
<li>
<p>forhøjet blodtryk </p>
</li>
<li>
<p>hoste </p>
</li>
<li>
<p>forstoppelse, diarré, mavesmerter </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>mundtørhed </p>
</li>
<li>
<p>oppustet mave, luft i maven, betændelse i maveslimhinden (gastritis) </p>
</li>
<li>
<p>unormale levertal i blodprøver </p>
</li>
<li>
<p>muskelspasmer, muskelsmerter, smerter i skuldre, arme eller ben, rygsmerter, forhøjet 
kreatinkinase i blodprøver (laboratorietest for muskelskade), muskelsvaghed, ledsmerter 
(artralgi) </p>
</li>
<li>
<p>forhøjet kreatinin og karbamid i blodet (laboratorietest for nyrefunktion) </p>
</li>
<li>
<p>usædvanlig træthed eller svaghed </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 patienter) </p>
<ul>
<li>
<p>hedeture </p>
</li>
<li>
<p>smerter i øvre maveregion, halsbrand, fordøjelsesbesvær </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>hævede ben eller hænder </p>
</li>
<li>
<p>nakkesmerter, brystsmerter, smerter </p>
</li>
<li>
<p>nedsat glomerulær filtrationshastighed (et mål for nyrefunktionen) </p>
</li>
</ul>
<p>Hyppighed ikke kendt (kan ikke estimeres ud fra forhåndenværende data) </p>
<ul>
<li>
<p>prikkende fornemmelse </p>
</li>
<li>
<p>depression </p>
</li>
<li>
<p>åndenød </p>
</li>
</ul>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nustendi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nustendi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og æsken efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel. Opbevares i den 
originale yderpakning for at beskytte mod fugt. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Nustendi indeholder: </p>
<ul>
<li>
<p>Aktive stoffer: bempedoinsyre og ezetimib. Hver filmovertrukket tablet indeholder 180 mg 
bempedoinsyre og 10 mg ezetimib. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>lactosemonohydrat (se til sidst i pkt. 2 under "Nustendi indeholder lactose og natrium") </p>
</li>
<li>mikrokrystallinsk cellulose (E460) </li>
<li>natriumstivelsesglycolat (type A) (se til sidst i pkt. 2 under "Nustendi indeholder lactose og 
natrium") </li>
<li>hydroxypropylcellulose (E463) </li>
<li>magnesiumstearat (E470b) </li>
<li>vandfri kolloid silica (E551) </li>
<li>natriumlaurylsulfat (E487) (se til sidst i pkt. 2 under "Nustendi indeholder lactose og 
natrium") </li>
<li>povidon (K30) (E1201) </li>
<li>delvist hydrolyseret polyvinylalkohol (E1203), talkum (E553b), titandioxid (E171), 
indigocarmin-aluminiumlak (E132), glycerolmonocaprylocaprat, brilliant blue FCF-
aluminiumlak (E133) </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Filmovertrukne tabletter, der er blå, ovale og præget med "818" på den ene side og "ESP" på den 
anden side. Tabletstørrelse: 15 mm × 7 mm × 5 mm. </p>
<p>Nustendi fås i plast/aluminium-blisterkort i æsker med 10, 14, 28, 30, 84, 90, 98 eller 
100 filmovertrukne tabletter eller enkeltdosisblisters i æsker med 10 x 1, 50 x 1 eller 
100 x 1 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført i Danmark. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Daiichi Sankyo Europe GmbH 
Zielstattstrasse 81379 München 
Tyskland </p>
<p>Fremstiller </p>
<p>Daiichi Sankyo Europe GmbH 
Luitpoldstrasse 1 
85276 Pfaffenhofen 
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Daiichi Sankyo Belgium N.V.-S.A 
Tél/Tel: +32-(0) 2 227 18 Lietuva 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
България 
Daiichi Sankyo Europe GmbH 
тел.: +49-(0) 89 7808 0 
Luxembourg/Luxemburg 
Daiichi Sankyo Belgium N.V.-S.A 
Tél/Tel: +32-(0) 2 227 18 Česká republika 
Zentiva, k.s. 
Tel: +420 267 241 Magyarország 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
Danmark 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 
Malta 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Deutschland 
Daiichi Sankyo Deutschland GmbH 
Tel: +49-(0) 89 7808 0 
Nederland 
Daiichi Sankyo Nederland B.V. 
Tel: +31-(0) 20 4 07 20 Eesti 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Norge 
Daiichi Sankyo Europe GmbH 
Tlf: +49-(0) 89 7808 0 
Ελλάδα 
Daiichi Sankyo Europe GmbH 
Τηλ: +49-(0) 89 7808 0 
Österreich 
Daiichi Sankyo Austria GmbH 
Tel: +43 (0) 1 485 86 42 0 
España 
Daiichi Sankyo España, S.A. 
Tel: +34 91 539 99 Polska 
Daiichi Sankyo Europe GmbH 
Tel.: +49-(0) 89 7808 0 
France 
Daiichi Sankyo France S.A.S. 
Tél: +33 (0) 1 55 62 14 Portugal 
Daiichi Sankyo Portugal, Unip. LDA 
Tel: +351 21 4232Hrvatska 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
România 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Ireland 
Daiichi Sankyo Ireland Ltd 
Tel: +353-(0) 1 489 3Slovenija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Ísland 
Daiichi Sankyo Europe GmbH 
Sími: +49-(0) 89 7808 0 
Slovenská republika 
Zentiva, a.s. 
Tel: +421 2 3918 3Italia 
Daiichi Sankyo Italia S.p.A. 
Tel: +39-06 85 2Suomi/Finland 
Daiichi Sankyo Europe GmbH 
Puh/Tel: +49-(0) 89 7808 0 
Κύπρος 
Daiichi Sankyo Europe GmbH 
Τηλ: +49-(0) 89 7808 0 
Sverige 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
Latvija 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 
United Kingdom (Northern Ireland) 
Daiichi Sankyo Europe GmbH 
Tel: +49-(0) 89 7808 0 </p>
<p>Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f38fd388d9d557d533fdef41848d682d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nustendi Package Leaflet for language en"
Description: "ePI document Bundle for nustendi Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f38fd388d9d557d533fdef41848d682d"
* entry[0].resource = composition-en-f38fd388d9d557d533fdef41848d682d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf38fd388d9d557d533fdef41848d682d"
* entry[=].resource = mpf38fd388d9d557d533fdef41848d682d
                            
                    
Instance: bundlepackageleaflet-da-f38fd388d9d557d533fdef41848d682d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nustendi Package Leaflet for language da"
Description: "ePI document Bundle for nustendi Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f38fd388d9d557d533fdef41848d682d"
* entry[0].resource = composition-da-f38fd388d9d557d533fdef41848d682d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf38fd388d9d557d533fdef41848d682d"
* entry[=].resource = mpf38fd388d9d557d533fdef41848d682d
                            
                    



Instance: mpf38fd388d9d557d533fdef41848d682d
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Nustendi 180 mg/10 mg film-coated tablets"
Description: "Nustendi 180 mg/10 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1424/001 - 011"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Nustendi 180 mg/10 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: f38fd388d9d557d533fdef41848d682dListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "nustendi"

* status = #current
* mode = #working

* title = "List of all ePIs associated with nustendi"

* subject = Reference(mpf38fd388d9d557d533fdef41848d682d)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#nustendi "nustendi"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f38fd388d9d557d533fdef41848d682d) // nustendi en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f38fd388d9d557d533fdef41848d682d) // nustendi da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f38fd388d9d557d533fdef41848d682d
InstanceOf: List

* insert f38fd388d9d557d533fdef41848d682dListRuleset
    